sar425899 glp-1 glucagon dual agonist sanofi Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity Receptor occupancy of dual glucagon-like

Some Medicare patients will be able to access GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more...

Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.

The science behind 24% weight loss results explained.

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes

Some sub-analyses of large clinical trials suggest that GLP-1RA and sodium-glucose cotransporter 2 inhibitor combination therapy may provide more significant reductions in heart failure hospitalization and renal composite events than each alone

Research shows that nearly 90% of people with type 2 diabetes also struggle with their weight, and these medications solve both problems at once